<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02287480</url>
  </required_header>
  <id_info>
    <org_study_id>CCER 14-221</org_study_id>
    <nct_id>NCT02287480</nct_id>
  </id_info>
  <brief_title>VSV-ZEBOV Geneva Vaccine Trial</brief_title>
  <acronym>VSV-ZEBOV</acronym>
  <official_title>A Phase I/II Dose-finding Randomized, Single-center, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Vesicular Stomatitis Virus-vectored Zaire Ebola Candidate Vaccine BPSC1001 (VSVΔG-ZEBOV) in Healthy Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Geneva</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Albert Schweitzer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, University of Tuebingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KEMRI-Wellcome Trust Collaborative Research Program</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hemorrhagic fever resulting from Ebola infection is frequently fatal; the current Ebola&#xD;
      outbreak, still in its ascendant phase, has a mortality rate over 50%. There is no proven&#xD;
      therapy or prevention available at this time.&#xD;
&#xD;
      The vaccine candidate VSV-ZEBOV (BPSC1001) has shown promising safety and efficacy in&#xD;
      preventing Ebola Zaire infections in non-human primates (NHP). Before it can be assessed in&#xD;
      large Phase IIb/3 trials in affected areas, safety data from phase 1 first-in-human trials&#xD;
      are needed. To accelerate this process, the World Health Organization (WHO) has constituted a&#xD;
      consortium of Clinical Research Centers in Switzerland, Germany, and Africa that will use&#xD;
      similar protocols to collectively include roughly 250 volunteers, the sample size required to&#xD;
      identify a 2-fold difference in anti-ZEBOV IgG antibody titers following immunization with 2&#xD;
      different doses of BPSC1001.&#xD;
&#xD;
      The joint primary objectives of this single-center, double-blind, randomized&#xD;
      placebo-controlled phase 1 dose-finding study are to assess the safety and tolerability of&#xD;
      the VSV-ZEBOV vaccine when administered to healthy volunteers at a lower or higher vaccine&#xD;
      dose and to define whether seroresponses differ significantly following immunization with the&#xD;
      lower or higher vaccine dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single-center, double-blind, randomized placebo-controlled phase 1 dose-finding study&#xD;
      will have two randomization schemes. Volunteers who could later be exposed to Ebolavirus&#xD;
      while working in epidemic areas (&quot;deployable subjects&quot;) will be randomized to receive one of&#xD;
      two vaccine doses. Non-deployable volunteers, with no identified risk of Ebola exposure in&#xD;
      the near term, will be allocated to one of three groups and receive the lower or higher&#xD;
      vaccine dose, or a placebo. A single immunization will be performed. All subjects will be&#xD;
      observed in the clinical trials unit (CTU) for 1.5 hours after vaccine/placebo injection.&#xD;
      Subjects will complete post-injection diaries for 7 days after injection, as well as&#xD;
      post-injection follow-up visits (see below). On-site visits at the CTU will occur on days -90&#xD;
      to -1, 0, 1, 3, 7, 14, 28, 84, 168. Some subjects with a positive serologic response at 24&#xD;
      weeks may be requested to return for immune durability testing at 12 months.&#xD;
&#xD;
      One or more interim analyses will be undertaken to guide decisions on 1) the potential use of&#xD;
      the vaccine in Ph2/3 trials in affected countries and 2) potential modification of the&#xD;
      trial(s) through an amendment to evaluate a higher dose, if immunogenicity is poor, or a&#xD;
      lower dose if the dosage levels selected are not safe and reasonably well tolerated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events with causal link to study intervention</measure>
    <time_frame>Days 0 - 14</time_frame>
    <description>Primary safety outcome</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Titers of ZEBOV-specific IgG antibodies</measure>
    <time_frame>Day 0 - 28</time_frame>
    <description>Primary immunogenicity outcome (required for dose selection)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of solicited local and systemic reactogenicity signs and symptoms</measure>
    <time_frame>Days 0 - 14</time_frame>
    <description>Day 0 is the day of the study intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unsolicited adverse events</measure>
    <time_frame>Days 0 - 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAE)</measure>
    <time_frame>Days 0 - 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude (copies/ml) of VSVΔG-ZEBOV viremia</measure>
    <time_frame>Days 1, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of change(s) from baseline for safety laboratory measures</measure>
    <time_frame>Days 1, 3, 7 &amp; 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of titers of ZEBOV-specific IgG antibodies</measure>
    <time_frame>Days 168</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titers of neutralizing ZEBOV-specific IgG antibodies</measure>
    <time_frame>Days 0, 7, 14, 28 and 168</time_frame>
    <description>This outcome will be evaluated in a subset of the first 46 vaccinees.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pattern of ZEBOV-specific T cell responses</measure>
    <time_frame>Days 0, 7, 14, 28 and 168</time_frame>
    <description>This outcome will be evaluated in a subset of the first 46 vaccinees.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of VSVΔG-ZEBOV viremia</measure>
    <time_frame>Days 1, 3 and 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnitude (copies/ml) of VSVΔG-ZEBOV shedding</measure>
    <time_frame>Days 1, 3 and 7</time_frame>
    <description>This outcome will be evaluated in a subset of vaccinees.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pattern of vaccine-induced innate responses</measure>
    <time_frame>Day 7</time_frame>
    <description>This outcome will be evaluated in a subset of the first 46 vaccinees.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patterns of changes in B and T cell responses / repertoire induced by VSV-ZEBOV immunization</measure>
    <time_frame>Days 0, 7, 14, 28 and 168</time_frame>
    <description>This outcome will be evaluated in a subset of the first 46 vaccinees.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Ebolavirus Disease</condition>
  <arm_group>
    <arm_group_label>VSV-ZEBOV lower dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intramuscular (deltoid) injection of a lower dose (10^7 plaque-forming units) of VSV-ZEBOV.&#xD;
Study amendment (01.2015) : One intramuscular (deltoid) injection of a markedly lower dose (3x 10^5 plaque-forming units) of VSV-ZEBOV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSV-ZEBOV higher dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intramuscular (deltoid) injection of a higher dose (5 x 10^7 pfu) of VSV-ZEBOV.&#xD;
Study amendment (01.2015) : interrupted</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One intramuscular (deltoid) injection of normal saline (0.5 ml)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VSV-ZEBOV</intervention_name>
    <description>See arm/group descriptions.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>VSV-ZEBOV higher dose</arm_group_label>
    <arm_group_label>VSV-ZEBOV lower dose</arm_group_label>
    <other_name>BPSC1001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Has provided written informed consent before screening&#xD;
&#xD;
          -  Adult male or non-pregnant, non-lactating female, ages 18 to 65 (inclusive) at the&#xD;
             time of screening&#xD;
&#xD;
          -  Free of clinically significant health problems, as determined by pertinent medical&#xD;
             history and clinical examination at study screening&#xD;
&#xD;
          -  Females of childbearing potential who are willing to use an effective method of&#xD;
             contraception, from at least 7 days prior to vaccination through the end of the study&#xD;
             period, and a double method from day 0 through day 28&#xD;
&#xD;
          -  Males who are willing to use effective contraception from day 0 through day 28:&#xD;
&#xD;
          -  Be willing to minimize blood and body fluid exposure of others for 7 days after&#xD;
             vaccination&#xD;
&#xD;
          -  Use of effective barrier prophylaxis, such as latex condoms, during penetrative sexual&#xD;
             intercourse (avoiding the sharing of needles, razors, or toothbrushes, avoiding&#xD;
             open-mouth kissing, be willing to refrain from blood donation during the course of the&#xD;
             study)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior receipt of an Ebolavirus or Marburgvirus vaccine, a VSV-vectored vaccine, or any&#xD;
             other investigational vaccine likely to impact on interpretation of the trial data&#xD;
&#xD;
          -  Serologic evidence of prior Ebola exposure&#xD;
&#xD;
          -  Has a household contact (HHC) who is immunodeficient, HIV-positive, pregnant, has an&#xD;
             unstable medical condition in the opinion of the investigator (e.g., New York Heart&#xD;
             Association Class ≥ II heart failure, severe debilitating asthma and/or chronic&#xD;
             obstructive pulmonary disease)&#xD;
&#xD;
          -  Works with livestock&#xD;
&#xD;
          -  History of severe local or systemic reactions to any vaccination or a history of&#xD;
             severe allergic reactions&#xD;
&#xD;
          -  Known allergy to the components of the BPSC1001 vaccine product&#xD;
&#xD;
          -  Receipt of investigational product up to 30 days prior to enrollment or ongoing&#xD;
             participation in another interventional clinical trial&#xD;
&#xD;
          -  Receipt of licensed vaccines within 14 days of planned study immunization (30 days for&#xD;
             live vaccines) or ongoing participation in another clinical interventional trial&#xD;
&#xD;
          -  Acute or chronic, clinically significant psychiatric, hematologic, pulmonary,&#xD;
             cardiovascular, or hepatic or renal functional abnormality as determined by the&#xD;
             Investigator based on medical history, physical exam, and/or laboratory screening test&#xD;
&#xD;
          -  Any baseline laboratory screening tests which is outside of acceptable range as&#xD;
             defined in the protocol: ALT, AST, creatinine, hemoglobin, platelet count, total white&#xD;
             blood cell count, urine protein, urine occult blood, urine glucose&#xD;
&#xD;
          -  Serologic evidence of hepatitis C infection, evidence of active hepatitis B infection&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, including&#xD;
             human immunodeficiency virus (HIV) infection, asplenia, cytotoxic therapy in the&#xD;
             previous 5 years, and/or diabetes&#xD;
&#xD;
          -  Any chronic or active neurologic disorder, including seizures, and epilepsy, excluding&#xD;
             febrile seizures as a child&#xD;
&#xD;
          -  Has a known history of Guillain-Barré Syndrome&#xD;
&#xD;
          -  Has an active malignancy or recent (&lt; 10 years) history of metastatic or hematologic&#xD;
             malignancy&#xD;
&#xD;
          -  Suspected or known alcohol and/or illicit drug abuse within the past 5 years&#xD;
&#xD;
          -  Pregnant or lactating female, or female who intends to become pregnant during the&#xD;
             study period&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the 120 days&#xD;
             preceding study entry or planned administration during the study period&#xD;
&#xD;
          -  History of blood donation within 30 days of enrollment or plans to donate within the&#xD;
             study period&#xD;
&#xD;
          -  Administration of chronic (&gt; 14 days) immunosuppressants or other immune-modifying&#xD;
             drugs within 6 months of study entry&#xD;
&#xD;
          -  Any other significant finding that, in the opinion of the investigator, would increase&#xD;
             the risk of the individual's having an adverse outcome by participating in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire-Anne Siegrist, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospita, Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals of Geneva</name>
      <address>
        <city>Geneva</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.vsv-ebola.ch</url>
    <description>Study website</description>
  </link>
  <results_reference>
    <citation>Agnandji ST, Huttner A, Zinser ME, Njuguna P, Dahlke C, Fernandes JF, Yerly S, Dayer JA, Kraehling V, Kasonta R, Adegnika AA, Altfeld M, Auderset F, Bache EB, Biedenkopf N, Borregaard S, Brosnahan JS, Burrow R, Combescure C, Desmeules J, Eickmann M, Fehling SK, Finckh A, Goncalves AR, Grobusch MP, Hooper J, Jambrecina A, Kabwende AL, Kaya G, Kimani D, Lell B, Lemaître B, Lohse AW, Massinga-Loembe M, Matthey A, Mordmüller B, Nolting A, Ogwang C, Ramharter M, Schmidt-Chanasit J, Schmiedel S, Silvera P, Stahl FR, Staines HM, Strecker T, Stubbe HC, Tsofa B, Zaki S, Fast P, Moorthy V, Kaiser L, Krishna S, Becker S, Kieny MP, Bejon P, Kremsner PG, Addo MM, Siegrist CA. Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. N Engl J Med. 2016 Apr 28;374(17):1647-60. doi: 10.1056/NEJMoa1502924. Epub 2015 Apr 1.</citation>
    <PMID>25830326</PMID>
  </results_reference>
  <results_reference>
    <citation>Huttner A, Dayer JA, Yerly S, Combescure C, Auderset F, Desmeules J, Eickmann M, Finckh A, Goncalves AR, Hooper JW, Kaya G, Krähling V, Kwilas S, Lemaître B, Matthey A, Silvera P, Becker S, Fast PE, Moorthy V, Kieny MP, Kaiser L, Siegrist CA; VSV-Ebola Consortium. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1/2 trial. Lancet Infect Dis. 2015 Oct;15(10):1156-1166. doi: 10.1016/S1473-3099(15)00154-1. Epub 2015 Aug 4.</citation>
    <PMID>26248510</PMID>
  </results_reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>November 2, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>March 7, 2016</last_update_submitted>
  <last_update_submitted_qc>March 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Siegrist Claire-Anne</investigator_full_name>
    <investigator_title>Director of Center for Vaccinology</investigator_title>
  </responsible_party>
  <keyword>Ebolavirus Vaccines</keyword>
  <pending_results>
    <submitted>October 10, 2018</submitted>
    <returned>February 20, 2019</returned>
    <submitted>January 2, 2020</submitted>
    <returned>January 14, 2020</returned>
    <submitted>September 28, 2021</submitted>
    <returned>October 26, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

